Concepedia

Yayan Zhang

YZ

Statistics

Publications

10

Citations

4K

H-Index

10

Active since

2016

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Institut Gustave Roussy

National Cancer Center Hospital East

Peter MacCallum Cancer Centre

Vall d'Hebron Hospital Universitari

Yayan Zhang is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, cancer immunotherapy, and medicine.

Publications per year

2016–2024

10

Publications

10

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

, , +11

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma

Pier Luigi Zinzani, Vincent Ribrag, Craig H. Moskowitz et al. · Blood · 2017 · 295 citations · Full text

, , +9

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

, , +16

Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Danny Rischin, Kevin J. Harrington, Richard Greil et al. · Journal of Clinical Oncology · 2019 · 132 citations

, , +14

Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment

Guillermo Garcia‐Manero, Martin S. Tallman, Giovanni Martinelli et al. · Blood · 2016 · 58 citations

, , +16

1–5 of 10